AR047744A1 - Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico - Google Patents
Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropicoInfo
- Publication number
- AR047744A1 AR047744A1 ARP050100570A ARP050100570A AR047744A1 AR 047744 A1 AR047744 A1 AR 047744A1 AR P050100570 A ARP050100570 A AR P050100570A AR P050100570 A ARP050100570 A AR P050100570A AR 047744 A1 AR047744 A1 AR 047744A1
- Authority
- AR
- Argentina
- Prior art keywords
- 6alkyl
- 4alkyl
- nr5r6
- group
- 6alkylnr5
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Compuestos, o sales o hidratos, procesos para su preparacion intermediarios usados en su preparacion, composiciones farmacéuticas que contienen dichos compuestos y el uso terapéutico de los mismos. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), en donde: P es arilo; si m = 1 entonces R1 se une a P en la posicion meta del anillo P respecto del punto de union de P con el anillo de 5 miembros, y si m = 2 entonces R1 se une a P en las posiciones 2 y 5 del anillo P con el anillo de 5 miembros; R1 se selecciona entre el grupo formado por hidroxi, halo, nitro, C1-6 alquilhalo, OC1-6alquilhalo, C1-6 alquilo, OC1-6alquilo, C2-6 alquenilo, OC2-6alquenilo, C2-6 alquinilo, OC2-6alquinilo, C0-6alquilC3- 6cicloalquilo, OC0-6alquilC3-6cicloalquilo, C0-6 alquilarilo, OC0-6alquilarilo, CHO, (CO)R5, O(CO)R5, O(CO)OR5, O(CN)OR5, C1-6alquilOR5, OC2-6alquilOR5, C1-6alquil(CO)R5, OC1-6alquil(CO)R5, C0-6alquilCO2R5, OC1-6alquilCO2R5, C0-6 alquilciano, OC2- 6alquilciano, C0-6alquilNR5R6, OC2-6alquilNR5R6, C1-6alquil(CO)NR5R6, OC1-6alquil(CO)NR5R6, C0-6alquilNR5(CO)R6, OC2-6alquilNR5(CO)R6, C0-6alquilNR5(CO)NR5R6, C0-6alquilSR5, OC2-6alquilSR5, C0-6alquil(SO)R5, OC2-6alquil(SO)R5, C0-6alquilSO2R5, OC2- 6alquilSO2R5, C0-6alquil(SO2)NR5R6, OC2-6alquil(SO2)NR5R6, C0-6alquilNR5(SO2)R6, OC2-6alquilNR5(SO2)R6, C0-6alquilNR5(SO2)NR5R6, OC2-6alquilNR5(SO2)NR5R6, (CO)NR5R6, O(CO)NR5R6, NR5OR6, C0-6alquilNR5(CO)OR6, OC2-6alquilNR5(CO)OR6, SO3R5 y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre el grupo formado por C, N, O y S; R5 y R6 se seleccionan en forma independiente entre un grupo formado por hidrogeno, C1-6 alquilo, C3-7 cicloalquilo y arilo; X1 y X2 se seleccionan en forma independiente entre el grupo formado por CR4, y N; X3 se selecciona entre el grupo formado por CR4, N y O; en donde al menos uno de X1, X2 y X3 no es N; R4 se selecciona entre el grupo formado por H, =O, C1-6 alquilo, OH; R3 se selecciona entre el grupo formado por H, C1-6 alquilo, hidroxi, C0-6 alquilciano, oxo, =NR5, =NOR5, C1-4 alquilhalo, halo, C3-7 cicloalquilo, O(CO)C1-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0-4alquilo, (SO2)C0- 4alquilo, OC1-4alquilo, C1-4alquilOR5 y C0-4alquilNR5R6; X4 se selecciona entre el grupo formado por CR7R8, NR7, O, S, SO y SO2; R7 y R8 se seleccionan en forma independiente entre un grupo formado por hidrogeno, C1-6 alquilo, C3-7 cicloalquilo y arilo; X5 y X6 se seleccionan en forma independiente entre el grupo formado por C, N, O y S; R2 se selecciona entre el grupo formado por hidroxi, C0-6 alquilciano, =NR5, =NOR5, C1-4 alquilhalo, halo, C1-6 alquilo, C3-6 cicloalquilo, C0-6 alquilarilo, C0-6 alquilheteroarilo, C0-6 alquilcicloalquilo, C0-6 alquilheterocicloalquilo, OC1-4alquilo, OC0-6alquilarilo, O(CO)C1-4alquilo, (CO)OC1-4alquilo, C0-4alquil(S)C0-4alquilo, C1-4alquil(SO)C0-4alquilo, C1-4alquil(SO2)C0-4alquilo, (SO)C0- 4alquilo, (SO2)C0-4alquilo, C1-4alquilOR5, C0-4alquilNR5R6 y un anillo de 5 o 6 miembros que contiene átomos seleccionados en forma independiente entre C, N, O y S, y en donde dicho anillo puede sustituirse con uno o más A; y cualquier C1-6 alquilo, arilo o heteroarilo definido bajo R1, R2 y R3 puede sustituirse con uno o más A; A se selecciona entre el grupo formado por hidrogeno, hidroxi, halo, nitro, oxo, C0-6 alquilciano, C0-4alquilC3-6cicloalquilo, C1-6 alquilo, C1-6 alquilhalo, OC1- 6alquilhalo, C2-6 alquenilo, C0-3 alquilarilo, C0-6alquilOR5, OC2-6alquilOR5, C1-6alquilSR5, OC2-6alquilSR5, (CO)R5, O(CO)R5, OC2-6alquilciano, OC1-6alquilCO2R5, O(CO)OR5, OC1-6alquil(CO)R5, C1-6alquil(CO)R5, NR5OR6, C1-6alquilNR5R6, OC2- 6alquilNR5R6, C0-6alquil(CO)NR5R6, OC1-6alquil(CO)NR5R6, OC2-6alquilNR5(CO)R6, C0-6alquilNR5(CO)R6, C0-6alquilNR5(CO)NR5R6, O(CO)NR5R6, C0-6alquil(SO2)NR5R6, OC2-6alquil(SO2)NR5R6, C0-6alquilNR5(SO2)R6, OC2-6alquilNR5(SO2)R6, SO3R5, C1- 6alquilNR5(SO2)NR5R6, OC2-6alquil(SO2)R5, C0-6alquil(SO2)R5, C0-6alquil(SO)R5, OC2-6alquil(SO)R5 y un anillo de 5 o 6 miembros que contiene uno o más átomos seleccionados en forma independiente entre el grupo formado por C, N, O y S; m se selecciona entre 1 y 2; n se selecciona entre 0, 1, 2, 3 y 4; p se selecciona entre 1 y 2; y sus sales de hidratos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US54528904P | 2004-02-18 | 2004-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR047744A1 true AR047744A1 (es) | 2006-02-15 |
Family
ID=34886127
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP050100570A AR047744A1 (es) | 2004-02-18 | 2005-02-17 | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico |
Country Status (17)
Country | Link |
---|---|
US (2) | US20070185178A1 (es) |
EP (1) | EP1720860A1 (es) |
JP (1) | JP2007523178A (es) |
KR (1) | KR20070027503A (es) |
CN (1) | CN101018779A (es) |
AR (1) | AR047744A1 (es) |
AU (1) | AU2005214375A1 (es) |
BR (1) | BRPI0507501A (es) |
CA (1) | CA2554894A1 (es) |
EA (1) | EA200601266A1 (es) |
IL (1) | IL177057A0 (es) |
NO (1) | NO20063468L (es) |
RU (1) | RU2006127575A (es) |
TW (1) | TW200604183A (es) |
UY (1) | UY28760A1 (es) |
WO (1) | WO2005080379A1 (es) |
ZA (1) | ZA200606313B (es) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006080533A1 (ja) * | 2005-01-31 | 2006-08-03 | Mochida Pharmaceutical Co., Ltd. | 3-アミノ-1,2,4-トリアゾール誘導体 |
AR058807A1 (es) | 2005-09-29 | 2008-02-27 | Astrazeneca Ab | 5-(fenilisoxazoletoxi)-triazol-3-il piridinas sustituidas, para el tratamiento de trastornos mediados por el receptor mglur5 |
TW200811156A (en) * | 2006-05-05 | 2008-03-01 | Astrazeneca Ab | mGluR5 modulators IV |
KR20100090777A (ko) * | 2007-10-19 | 2010-08-17 | 아스트라제네카 아베 | 대사성 글루타메이트 수용체 (mglur)의 조절제로서의 테트라졸 유도체 |
WO2009054790A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | Amide linked heteroaromatic derivatives as modulators of mglur5 |
WO2009054785A1 (en) * | 2007-10-26 | 2009-04-30 | Astrazeneca Ab | 1,2,4-triazole ether derivatives as modulators of mglur5 |
JP2011500798A (ja) * | 2007-10-26 | 2011-01-06 | アストラゼネカ・アクチエボラーグ | mGluR5のモジュレーターとしてのアミノ1,2,4−トリアゾール誘導体 |
CN101643451B (zh) * | 2008-08-07 | 2013-03-06 | 浙江海正药业股份有限公司 | 过氧化物酶增殖物激活受体亚型δ类激动剂化合物及其制备方法 |
US20100114146A1 (en) * | 2008-10-30 | 2010-05-06 | Albrecht Thomas E | Methods and devices for predicting intra-gastric satiety and satiation creation device system performance |
KR20110089868A (ko) * | 2008-12-12 | 2011-08-09 | 아스트라제네카 아베 | 4-[4-메틸-5-(c1-10알킬티오/c5-10아릴-c1-6알킬티오)-4h-1,2,4-트리아졸-3-일]피리딘을 제조하기 위한 신규 방법 |
US20110306768A1 (en) * | 2008-12-18 | 2011-12-15 | Astrazeneca Ab | Processes for the manufacture of 3--pyridine, 4-methyl-3-methylthio-5-(3-pyridyl)-l,2,4-triazole, and (1r)-1-[2-(3-methylphenyl)-2h-tetrazol-5-yl]ethanol |
US8349852B2 (en) | 2009-01-13 | 2013-01-08 | Novartis Ag | Quinazolinone derivatives useful as vanilloid antagonists |
US20100273805A1 (en) * | 2009-04-23 | 2010-10-28 | Astrazeneca Ab | Sulphide bridged derivatives as modulators of mglur5 733 |
WO2011092293A2 (en) | 2010-02-01 | 2011-08-04 | Novartis Ag | Cyclohexyl amide derivatives as crf receptor antagonists |
US20120295942A1 (en) | 2010-02-01 | 2012-11-22 | Nicholas James Devereux | Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists |
ES2527849T3 (es) | 2010-02-02 | 2015-01-30 | Novartis Ag | Derivados de ciclohexilamida como antagonistas del receptor de CRF |
CN103189370B (zh) * | 2010-11-09 | 2015-07-08 | 霍夫曼-拉罗奇有限公司 | 作为gaba受体用配体的三唑衍生物 |
WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
CA2894281C (en) | 2012-12-20 | 2021-04-20 | Inception 2, Inc. | Triazolone compounds and uses thereof |
PE20160880A1 (es) | 2013-09-06 | 2016-09-22 | Inception 2 Inc | Compuestos de triazolona y usos de los mismos |
CN107935988A (zh) | 2013-10-14 | 2018-04-20 | 卫材R&D管理有限公司 | 选择性取代的喹啉化合物 |
TWI702218B (zh) | 2013-10-14 | 2020-08-21 | 日商衛材R&D企管股份有限公司 | 選擇性經取代之喹啉化合物 |
ES2791252T3 (es) | 2014-08-15 | 2020-11-03 | Janssen Pharmaceuticals Inc | Pirazoles |
PT3180329T (pt) | 2014-08-15 | 2020-06-08 | Janssen Pharmaceuticals Inc | Triazóis como inibidores do recetor nr2b |
WO2017007938A1 (en) | 2015-07-09 | 2017-01-12 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as glun2b receptor modulators |
MX2018009752A (es) * | 2016-02-10 | 2019-02-07 | Janssen Pharmaceutica Nv | 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b. |
AR108838A1 (es) | 2016-06-21 | 2018-10-03 | Bristol Myers Squibb Co | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa |
TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之1H-咪唑並[4,5-b]吡啶-2(3H)-酮及其作為GLUN2B受體調節劑之用途 |
KR20200067850A (ko) | 2017-10-06 | 2020-06-12 | 포르마 세라퓨틱스 인크. | 유비퀴틴 특이적 펩티다제 30의 억제 |
US11008302B2 (en) | 2018-04-04 | 2021-05-18 | Janssen Pharmaceutica Nv | Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators |
RS64321B1 (sr) | 2018-10-05 | 2023-08-31 | Forma Therapeutics Inc | Fuzionisani pirolini koji se ponašaju kao inhibitori ubikvitin specifične proteaze 30 (usp30) |
US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
KR20220024512A (ko) | 2019-06-14 | 2022-03-03 | 얀센 파마슈티카 엔.브이. | 치환된 헤테로방향족 피라졸로-피리딘 및 GluN2B 수용체 조절제로서의 이의 용도 |
AU2020292994A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyrazines and their use as GluN2B receptor modulators |
EP3983074A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Pyridine carbamates and their use as glun2b receptor modulators |
WO2020249792A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
US11161846B2 (en) | 2019-06-14 | 2021-11-02 | Janssen Pharmaceutica Nv | Substituted pyrazolo[4,3-b]pyridines and their use as GluN2B receptor modulators |
BR112021023562A2 (pt) | 2019-06-14 | 2022-01-04 | Janssen Pharmaceutica Nv | Carbamatos de pirazina e seus usos como moduladores do receptor de glun2b |
CN110669017B (zh) * | 2019-10-11 | 2023-08-04 | 成都麻沸散医药科技有限公司 | 多取代三唑甲酸酯类衍生物及其用途 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4303109B2 (ja) * | 2001-10-04 | 2009-07-29 | メルク エンド カムパニー インコーポレーテッド | 代謝共役型グルタミン酸受容体−5のヘテロアリール置換テトラゾール調節剤 |
DE60235114D1 (de) * | 2001-11-01 | 2010-03-04 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
DE60334781D1 (de) * | 2002-03-12 | 2010-12-16 | Merck Sharp & Dohme | Di-aryl-substituierte tetrazol-modulatoren des metabotropen glutamat-rezeptors-5 |
RU2352568C9 (ru) * | 2002-08-09 | 2009-06-27 | Астразенека Аб | [1,2,4]оксадиазолы (варианты), способ их получения, фармацевтическая композиция и способ ингибирования активации метаботропных глютаматных рецепторов-5 |
WO2004014902A2 (en) * | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
-
2005
- 2005-02-17 RU RU2006127575/04A patent/RU2006127575A/ru not_active Application Discontinuation
- 2005-02-17 US US10/588,751 patent/US20070185178A1/en not_active Abandoned
- 2005-02-17 CN CNA2005800102818A patent/CN101018779A/zh active Pending
- 2005-02-17 CA CA002554894A patent/CA2554894A1/en not_active Abandoned
- 2005-02-17 BR BRPI0507501-7A patent/BRPI0507501A/pt not_active IP Right Cessation
- 2005-02-17 AR ARP050100570A patent/AR047744A1/es not_active Application Discontinuation
- 2005-02-17 JP JP2006554231A patent/JP2007523178A/ja active Pending
- 2005-02-17 EA EA200601266A patent/EA200601266A1/ru unknown
- 2005-02-17 WO PCT/US2005/005200 patent/WO2005080379A1/en active Application Filing
- 2005-02-17 TW TW094104645A patent/TW200604183A/zh unknown
- 2005-02-17 EP EP05723281A patent/EP1720860A1/en not_active Withdrawn
- 2005-02-17 KR KR1020067015941A patent/KR20070027503A/ko not_active Application Discontinuation
- 2005-02-17 AU AU2005214375A patent/AU2005214375A1/en not_active Abandoned
- 2005-02-18 US US11/060,366 patent/US20060019997A1/en not_active Abandoned
- 2005-02-18 UY UY28760A patent/UY28760A1/es unknown
-
2006
- 2006-07-25 IL IL177057A patent/IL177057A0/en unknown
- 2006-07-28 NO NO20063468A patent/NO20063468L/no not_active Application Discontinuation
- 2006-07-28 ZA ZA200606313A patent/ZA200606313B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
RU2006127575A (ru) | 2008-03-27 |
NO20063468L (no) | 2006-11-15 |
TW200604183A (en) | 2006-02-01 |
IL177057A0 (en) | 2006-12-10 |
WO2005080379A1 (en) | 2005-09-01 |
JP2007523178A (ja) | 2007-08-16 |
AU2005214375A1 (en) | 2005-09-01 |
UY28760A1 (es) | 2005-06-30 |
EA200601266A1 (ru) | 2007-02-27 |
ZA200606313B (en) | 2007-03-28 |
EP1720860A1 (en) | 2006-11-15 |
CN101018779A (zh) | 2007-08-15 |
BRPI0507501A (pt) | 2007-06-26 |
CA2554894A1 (en) | 2005-09-01 |
US20060019997A1 (en) | 2006-01-26 |
KR20070027503A (ko) | 2007-03-09 |
US20070185178A1 (en) | 2007-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR047744A1 (es) | Compuestos de triazol y su uso como antagonistas del receptor de glutamato metabotropico | |
AR047812A1 (es) | Compuestos de tetrazol y su uso como antagonistas del receptor de glutamato metabotropico | |
AR047966A1 (es) | Compuestos poliheterociclicos y su uso como antagonistas del receptor de glutamato metabotropico | |
AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
AR061923A1 (es) | Compuestos derivados de benzofuran-piperidina | |
AR048065A1 (es) | Compuestos de piperazina acetilinica y su uso como antagonistas del receptor de glutamato metabotropico | |
AR057987A1 (es) | Compuestos agonistas de cb1 (receptor cannabinoide) | |
AR049706A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
AR054529A1 (es) | Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6 | |
AR059176A1 (es) | Compuesto de indol, composicion farmaceutica que lo comprende, metodo para prepararlo y su uso para preparar dicha composicion y para la manufactura de un medicamento para el tratamiento o prevencion de leiomiomas y endometriosis. | |
PE20221253A1 (es) | Inhibidores de pequenas moleculas de mutante g12c de kras | |
PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
AR052458A1 (es) | Amino-imidazolonas para la inhibicion de beta-secretasa | |
CO6220949A2 (es) | Derivados pirazolicos como inhibidores de la 11 beta -hsd1 | |
AR049708A1 (es) | Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos | |
AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
AR082562A1 (es) | Derivados de isoxazolina como agentes antiparasitarios | |
AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
AR056103A1 (es) | Compuestos de(piran-piperidinil)benzimidazol, composiciones farmaceuticas que los comprenden, proceso de preparacion y usos en el tratamiento de afecciones mediadas por agonistas del receptor muscarinico m1 | |
AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
AR049331A1 (es) | Derivados de imidazopiridinas, imidazoquinolinas e iimidazonaftiridinas sustituidas con amidas como moduladores de biosintesis de citoquinas. composiciones farmaceuticas. | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
AR088449A1 (es) | Benzilindazoles sustituidos | |
AR075084A1 (es) | Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes | |
AR061372A1 (es) | Amino-imidazoles y sus usos como medicamentos para el tratamiento de mal de alzheimer, demencia y neurodegeneracion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |